The brain trancytosome: pooled in vivo screening of 1000s of biologics discovers novel “portal” receptors and mechanisms for macromolecule CNS delivery
These newly identified Portal receptors may enable unprecedented control over biodistribution, enhancing CNS delivery, cell-type specificity, regional targeting, and reduced peripheral effects. By substantially expanding the known Portal landscape, our work provides a foundation for developing biologics with precisely engineered tissue distribution profiles that are sculpted to meet the intended product profiles for specific therapeutic approaches. The Transcytosome represents a crucial step toward realizing the full therapeutic potential of biologics in CNS diseases such as Alzheimer's.
Authors
- Glenn Hauk (ORCID: https://orcid.org/0000-0003-4325-7335)
- Marshall Case (ORCID: https://orcid.org/0000-0002-1504-4802)
- Brian T. Wipke
- Shane Lofgren
- Karen E. Duffy (ORCID: https://orcid.org/0000-0002-5673-2863)
- Naveen K. Mehta
- Alvaro Cabrera Garcia
- Ainaz Malekoltojari (ORCID: https://orcid.org/0000-0002-7352-8776)
- Allie Braun
- Kate Nudel
- Alex Gerew
- Fabliha Anam
- Supriva Ravichandran
- Alex Reis
- Isabel Albuja
- Erik Swanson
- Manan Shah
- Anisha Anand
- Gleb Kuznetsov
- Jack Gourdeau
- Kimberly Scearce‐Levie
- Mike Nichols
- Roasa Mehmood
- Hala Haddad
- Pierce Ogden
- Sean Carroll
- John Avera
- Maggie Prescott
- Tianxiao Sun
- Yendee Ho‐Rath
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103983
- Primary Topic
- Barrier Structure and Function Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00